More articles from Myelodysplastic Syndromes

Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling
Daniel A. Pollyea, Chelsea Harris, Jennifer L. Rabe, Brenna R. Hedin, Lesly De Arras, Sigrid Katz, Emily Wheeler, Rafael Bejar, Matthew J. Walter, Craig T. Jordan, Eric M. Pietras, Scott Alper

Haematologica Mar 2019, haematol.2018.214155; DOI: 10.3324/haematol.2018.214155
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
Sophie Park, Olivier Kosmider, Frédéric Maloisel, Bernard Drenou, Nicolas Chapuis, Thibaud Lefebvre, Zoubida Karim, Hervé Puy, Anne Sophie Alary, Sarah Ducamp, Frédérique Verdier, Cécile Bouilloux, Alice Rousseau, Marie-Christine Jacob, Agathe Debliquis, Agnes Charpentier, Emmanuel Gyan, Bruno Anglaret, Cecile Leyronnas, Selim Corm, Borhane Slama, Stephane Cheze, Kamel Laribi, Shanti Amé, Christian Rose, Florence Lachenal, Andrea Toma, Gian Matteo Pica, Martin Carre, Frédéric Garban, Clara Mariette, Jean-Yves Cahn, Mathieu Meunier, Olivier Herault, Pierre Fenaux, Orianne Wagner-Ballon, Valerie Bardet, Francois Dreyfus, Michaela Fontenay

Haematologica Mar 2019, 104 (3) 497-504; DOI: 10.3324/haematol.2018.203158
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
Peipei Lin, Yanling Ren, Xiaomei Yan, Yingwan Luo, Hua Zhang, Meenu Kesarwani, Jiachen Bu, Di Zhan, Yile Zhou, Yuting Tang, Shuanghong Zhu, Weilai Xu, Xinping Zhou, Chen Mei, Liya Ma, Li Ye, Chao Hu, Mohammad Azam, Wei Ding, Jie Jin, Gang Huang, Hongyan Tong

Haematologica Mar 2019, 104 (3) 485-496; DOI: 10.3324/haematol.2018.197749
Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance
Rakchha Chhetri, Li Yan A. Wee, Romi Sinha, Monika M. Kutyna, Anh Pham, Helen Stathopoulos, Lakshmi Nath, Shriram V. Nath, Nicholas Wickham, Timothy Hughes, Deepak Singhal, David J. Roxby, Devendra K. Hiwase

Haematologica Feb 2019, haematol.2018.215087; DOI: 10.3324/haematol.2018.215087
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, Pierre Fenaux

Haematologica Feb 2019, haematol.2018.207118; DOI: 10.3324/haematol.2018.207118
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T cell clusters as response pattern to lenalidomide
Thorben Mährle, Nuray Akyüz, Pim Fuchs, Nicola Bonzanni, Donjete Simnica, Ulrich Germing, Anne Marie Asemissen, Johann-Christoph Jann, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak, Mascha Binder

Haematologica Jan 2019, haematol.2018.208223; DOI: 10.3324/haematol.2018.208223
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Nico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, Dietrich Beelen, Liesbeth de Wreede, Ghulam Mufti, Nina Simone Knelange, Dietger Niederwieser, Lone S Friis, Gerhard Ehnninger, Arnon Nagler, Ibrahim Yakoub-Agha, Ellen Meijer, Per Ljungman, Johan Maertens, Lothar Kanz, Lucia Lopez-Corral, Arne Brecht, Charles Craddock, Jürgen Finke, Jan J Cornelissen, Paolo Bernasconi, Patrice Chevallier, Jorge Sierra, Marie Robin, Nicolaus Kröger

Haematologica Jan 2019, haematol.2018.200808; DOI: 10.3324/haematol.2018.200808
Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome
Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp N. Sander, Heiko Becker, Pierre W. Wijermans, Christoph Plass, Dieter Weichenhan, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Haematologica Jan 2019, 104 (1) 59-69; DOI: 10.3324/haematol.2017.187278
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, John F. Seymour, Australasian Leukaemia and Lymphoma Group

Haematologica Dec 2018, haematol.2018.201152; DOI: 10.3324/haematol.2018.201152
A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)
Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thosten Braun, Jacques Delaunay, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux, GROUPE FRANCOPHONE DES MYELODYSPLASIES

Haematologica Oct 2018, haematol.2018.203885; DOI: 10.3324/haematol.2018.203885

More articles from Myelodysplastic Syndromes

Pages